An investigational drug that legally exists only inside Eli Lilly's trials is being sold online anyway — and it owns the worst harm record in the peptide file: death reports, hospitalizations, and tripling poison-center calls.
The starting fact
Retatrutide is an experimental Eli Lilly drug. It has never been approved anywhere, and authentic retatrutide exists only inside Lilly’s monitored clinical trials. Everything sold to consumers under that name is, by definition, not the studied drug — it is an unverified product wearing an investigational drug’s name. Eli Lilly states that suspect products it tested contained too much, too little, or the wrong active ingredient, plus contaminants.
That distinction matters for everything below: the accurate phrase is never “retatrutide caused,” but always “a product sold as retatrutide was reported.”
Two death reports — with the caveats printed at full size
CBS News (October 13, 2026), working from FDA adverse-event reports obtained under FOIA, reported two deaths following use of products sold as retatrutide:
- A 41-year-old woman — cardiac arrest; the report, filed in July 2026 by a healthcare professional, described a product from an unreliable source.
- A 49-year-old woman — severe dehydration, malnutrition, cardiac arrest; the report, received in September 2026, said a licensed nurse had convinced her to buy retatrutide from an online seller.
Neither report is verified. FDA declined to say whether it investigated. A report to the FDA’s adverse-event system is not a causal finding — it is an allegation entered into a database, about a product whose identity cannot be confirmed. We print these reports because they exist and because readers deserve the record; we print the caveats in the same size type because the record deserves accuracy more than it deserves drama.
The hospitalizations, counted
Public Citizen’s investigation (June 16, 2026) counted 14 reported hospitalizations in FDA’s system tied to retatrutide products. Case details in the record include tachycardia, ketoacidosis, and acute necrotizing pancreatitis. The count has grown through 2026: 10 reports in 2025, four involving hospitalization; 26 reports in the first five months of 2026, 11 of them hospitalizations, three described as life-threatening.
Poison centers: the trend is the story
America’s Poison Centers began counting retatrutide exposures only in late 2025. The counts since (via CBS News, October 2026):
- Q1 2026: 249 exposures
- Q2 2026: 460 exposures
- Q3 2026: 862 exposures
That is a 265% rise from late 2025, averaging about 95 calls a month in early 2026 and accelerating. “Exposure” includes calls about use without a serious outcome — the trend line, not any single call, is the publishable fact: each quarter, roughly twice as many people are calling poison control about a drug that is not legally sold to anyone.
The warning letters didn’t close the sellers
FDA sent 14 warning letters to retatrutide sellers starting in December 2024. As of May 2026, Public Citizen found 11 of the 14 were still advertising unapproved peptides — and 8 were still selling retatrutide. The enforcement record is not a reassurance; it is a measurement of how little a warning letter interrupts this market.
Identity failures are not hypothetical, either: four injectables bought at a Brooklyn convenience store — labeled BPC-157, PT-141, retatrutide, and NAD+ — were sent to independent tester Finnrick Analytics by WIRED (September 15, 2026). None contained a detectable match for its labeled ingredient.
Get medical care now if
- A racing heartbeat, faintness, or chest symptoms after using a product sold as retatrutide.
- Severe or persistent vomiting or diarrhea, or inability to keep fluids down — dehydration is a thread running through the documented cases.
- Severe abdominal pain — pancreatitis, including a necrotizing case, is in this record.
Tell the treating clinician exactly what the product was sold as, and keep the vial if you can — product identity is the first question in every one of these cases. If you were harmed, report it to FDA MedWatch. Compounders and gray-market sellers are not required to report adverse events; the record only grows when patients file.
The bottom line
Every other compound on this site has the same honest problem — too little human data. Retatrutide is different in kind: it has an accumulating harm record attached to products whose identity cannot be verified, sold by companies that kept selling after federal warnings. There is no careful way to buy an investigational drug from a convenience-store supply chain. See also Contaminated Products & Forged Lab Reports and The Vial Problem.
Educational information only — not medical or legal advice. Status as of November 9, 2026. See Our Legal Mandate.